Adamis Pharmaceuticals received FDA approval for its Symjepi, or epinephrine prefilled syringe, a generic version of EpiPen intended for treatment of allergic reactions including anaphylaxis. The company is planning to file a second new-drug application for a junior version of Symjepi with the agency.
Adamis' generic EpiPen wins FDA nod
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.